Collateral for a security interest recorded Feb 7, 2025 (Hayfin Services LLP).
Term ended Jun 7, 2026 · High confidence
20-year base term ended Jun 7, 2026
Held by Revance Therapeutics, Inc.
Filed Sep 14, 2015 as application 14/852,990 · Granted Oct 15, 2019
Base term, 20 years from filing
Today
Term ended Jun 7, 2026
2006
2026
Clock starts
Jun 7, 2006
Jun 7, 2006
Term ended
Jun 7, 2026
Jun 7, 2026
Granted
Oct 15, 2019
Oct 15, 2019
base term
after the term ends
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,926,991, to Jun 7, 2026. The term already ends on or before that date, so the cap shortened nothing.
1 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
21
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 7, 2006, when application 11/447,984, the earliest non-provisional in its chain, was filed (this one was filed Sep 14, 2015) | Jun 7, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,926,991) | resolves to Jun 7, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 1 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Jun 7, 2026 | High confidence |
This family
| US 8,926,991 | In force Oct 2028 | Oct 2028 |
| Application 14/464,740 | Abandoned not computed | not computed |
| Application 14/552,755 | Abandoned not computed | not computed |
| Application 14/555,870 | Abandoned not computed | not computed |
| Application 14/573,659 | Abandoned not computed | not computed |
| Application 14/722,990 | Abandoned not computed | not computed |
| Application 14/753,917 | Abandoned not computed | not computed |
| US 10,441,641 | this patent Jun 2026 | Jun 2026 |
8 of 21 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 24, 2016 Reel 38096, frame 402 | Botulinum Toxin Research Associates, Inc. | Borodic, Gary E. | Assignment of Assignor's Interest |
| Mar 24, 2016 Reel 38249, frame 590 | Borodic, Gary e, DR | Botulinum Toxin Research Associates, Inc. | Assignment of Assignor's Interest |
| Jun 3, 2016 Reel 38870, frame 160 | Botulinum Toxin Research Associates, Inc. | Revance Therapeutics, Inc. | Assignment of Assignor's Interest |
| Mar 18, 2022 Reel 59437, frame 654 | Revance Therapeutics, Inc. | Athyrium Buffalo LP | Security Interest |
| Feb 7, 2025 Reel 70153, frame 630 | Athyrium Buffalo LP | Revance Therapeutics, Inc. | Release of Security Interest |
| Feb 7, 2025 Reel 70153, frame 663 | Revance Therapeutics, Inc.; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 7, 2025 Reel 70153, frame 736 | Revance Therapeutics, Inc.; Bellus Medical, LLC; Crown Laboratories, Inc. | Hayfin Services LLP, as Administrative Agent | Security Interest |
| Feb 17, 2025 Reel 70239, frame 739 | Revance Therapeutics, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,926,991, ends no earlier than this term, so it caps nothing.
Citations
3
later US patents cite this one
That is below the median of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.